ArticleInternational journal of hypertension2025
B-Type Natriuretic Peptide as a Marker of Subclinical Heart Disease in a High-Burden Emergency Department Population With Sustained Asymptomatic Hypertension.
Article in International journal of hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- B-Type Natriuretic Peptide as a Marker of Subclinical Heart Disease in a High-Burden Emergency Department Population With Sustained Asymptomatic Hypertension.International journal of hypertension · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
B-Type natriuretic peptide (BNP) levels below contemporary thresholds for diagnosing congestive heart failure are associated with subclinical heart disease (SHD) and adverse cardiovascular outcomes in community patients with uncontrolled asymptomatic hypertension. This study aimed to determine the accuracy of BNP for detecting SHD in emergency patients with sustained asymptomatic hypertension, where SHD is universally prevalent. Conducted at two urban academic emergency departments within a seven-hospital healthcare organization, this proof-of-concept study included adults with sustained asymptomatic hypertension (initial BP ≥ 160/100 mmHg and second BP ≥ 140/90 mmHg), excluding those with congestive heart failure, renal insufficiency, atrial fibrillation, pregnancy, incarceration, cognitive impairment, and symptomatic hypertension. Enrolled patients underwent bedside echocardiograms, BNP lab tests, and electrocardiograms. All 78 patients (100%) had SHD. The cohort was predominantly female (55.1%), middle-aged (mean age: 52 ± 15.2 years), with Class I obesity (mean BMI: 32.3 ± 8.3) and a high prevalence of hypertension history (55.1%). Common findings included left ventricular hypertrophy (86%), diastolic dysfunction (70.5%), and left ventricular systolic dysfunction (12.2%). The BNP lab test accurately detected SHD in nearly 60% of patients, with a Type II error rate of approximately 40%. In this proof-of-concept study, BNP underperformed in a cohort with universally present SHD, suggesting that sole reliance on BNP may lead to missed opportunities for early intervention.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.